La vendita allo scoperto per SunLink Health Systems dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di SunLink Health Systems. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

SunLink Health Systems (AMEX:SSY) Azioni, Report sulle vendite allo scoperto

SunLink Health Systems

SunLink Health Systems Inc is engaged in providing retail pharmacy services. The company operates its business through segments namely the Healthcare Services segment and Pharmacy segment. The Healthcare Services segment includes subsidiaries that own and operate licensed-bed, acute care hospitals, which includes bed geriatric psychology unit, and nursing home; own medical buildings, which are leased to unaffiliated healthcare providers, and adjacent vacant land; and provides information technology to outside customers. The Pharmacy segment, which is the key revenue generator is composed of retail pharmacy products and services that are conducted in rural markets; institutional pharmacy services; pharmacy services; and durable medical equipment.

SunLink Health Systems, Inc. Common Stock

SunLink Health Systems Inc

SENSYNE HEALTH LTD by Sensyne Health Ltd.

Sassy Gold Corp Ordinary Shares

Sassy Gold Corp

Stratasys Ltd

WIIM

SunLink Health Systems shares are trading higher after the company announced it's urging shareholders to vote for a majority approval merger with Regional Health Properties.

Over 99% of the SunLink shares voted to date have shown support "FOR" the merger proposal, but additional votes are needed in order to approve SunLink's proposed merger with Regional

News

Reported Earlier, SunLink Urges Shareholders To Vote FOR Merger With Regional Health Properties By July 28 As Majority Approval Threshold Looms

SunLink Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSY#NYSE">SSY</a>) today issued the following update with respect to its scheduled $0.10 per share special cash dividend approved by SunLink's Board of Directors and previously announced on July 18, 2025 (the "Special Cash Dividend").
SunLink understands that trades of SunLink common stock entered into during the period (the "due bill period") beginning July 29, 2025 (the record date for the Special Cash Dividend) and through July 30, 2025 (the payment date for the Special Cash Dividend) will have a due bill attached for the Special Cash Dividend. Due bills obligate sellers to deliver the Special Cash Dividend to the buyer. This means that persons who purchase SunLink common stock during the due bill period are entitled to receive the Special Cash Dividend, and persons who sell the stock during the due bill period are not entitled to the Special Cash Dividend. Accordingly, if an investor wishes to receive the Special Cash Dividend, the investor will need to hold the SunLink common stock securities through and including the payment date of July 30, 2025.

Dividends

SunLink Confirms $0.10 Special Dividend, Says Investors Must Hold Shares Through July 30, 2025 To Receive Payment

UPDATE: Announced July 18, 2025, SunLink Health Systems Declares Special Cash Dividend $0.10/Share

As previously disclosed, on April 14, 2025, SunLink Health Systems, Inc., a Georgia corporation ("SunLink"), entered into an Amended and Restated Agreement and Plan of Merger (the "Amended and Restated Merger Agreement") with Regional Health Properties, Inc., a Georgia corporation ("Regional"). The Amended and Restated Merger Agreement amended and restated in its entirety the previously announced Agreement and Plan of Merger, between Regional and SunLink, dated as of January 3, 2025 . On June 22, 2025, SunLink and Regional entered into an Amendment to the Amended and Restated Agreement and Plan of Merger, pursuant to which Regional and SunLink each agreed to extend the Termination Date (as defined in the Amended and Restated Merger Agreement) until 5:00 p.m., Eastern time, on August 11, 2025 and make a clarifying clean-up change.The Amended and Restated Merger Agreement, as amended (the "Merger Agreement"), provides that, among other things and subject to the terms and conditions of the Merger Agreement, SunLink will be merged with and into Regional (the "Merger"), with Regional surviving the Merger.
&nbsp;
Pursuant to the terms and conditions of the Merger Agreement, SunLink may pay, declare or set aside, as applicable, one or two special cash dividends to holders of shares of common stock, no par value per share, of SunLink ("SunLink Common Stock"). Subject to any upward adjustment pursuant to the terms and conditions of the Merger Agreement by reason of any Regional Debt Distress (as defined in the Merger Agreement), the SunLink special cash dividends are an amount not to exceed in the aggregate the sum of (i) $705,000, plus (ii) an amount, if any, by which the sum of the SunLink Cash and Cash Equivalents (as defined in the Merger Agreement) is in excess of $6,000,000 (subject to adjustment as provided in the Merger Agreement) calculated within a period of five days prior to the closing of the Merger (the "Closing"); provided that in no event shall the total of such dividends exceed in the aggregate $1,000,000, subject to adjustment pursuant to the terms and conditions of the Merger Agreement.
&nbsp;
&nbsp;
On July 18, 2025, the Board of Directors of SunLink (the "SunLink Board") declared a special cash dividend payable to holders of SunLink Common Stock of record as of the close of business on Tuesday, July 29, 2025 (the "Record Date"), in the amount of $0.10 per share and payable on July 30,2025 (the "Payment Date").

SunLink Health Systems Declares $0.10 Per Share Special Cash Dividend Ahead Of Merger With Regional Health; Merger Deadline Extended To August 11, 2025

Trading Ideas

SunLink Health Systems Shares Halted, News Pending

<h3>Gainers</h3>
<ul>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock increased by 37.4% to $25.26 during Wednesday's after-market session. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares increased by 9.34% to $0.42. The market value of their outstanding shares is at $15.4 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) stock increased by 5.96% to $22.19. The market value of their outstanding shares is at $298.8 million. </li>
<li>PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) stock increased by 5.1% to $1.27. The market value of their outstanding shares is at $53.4 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) stock rose 5.0% to $1.05. The market value of their outstanding shares is at $7.0 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares increased by 4.99% to $0.92. The market value of their outstanding shares is at $5.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) shares fell 11.3% to $2.6 during Wednesday's after-market session. The market value of their outstanding shares is at $102.9 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock decreased by 7.82% to $3.94. The market value of their outstanding shares is at $72.3 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) stock fell 6.69% to $15.22. The market value of their outstanding shares is at $701.1 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock declined by 6.43% to $1.02. The market value of their outstanding shares is at $19.7 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock declined by 6.25% to $0.8. The company's market cap stands at $52.7 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares decreased by 6.06% to $4.5. The company's market cap stands at $9.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATHA

ATNF

HCWB

KAPA

MAZE

NVNO

OKYO

PDSB

PTHL

SRPT

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares moved upwards by 24.9% to $0.42 during Tuesday's after-market session. The market value of their outstanding shares is at $7.6 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) shares increased by 10.0% to $1.1. The company's market cap stands at $7.1 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) shares increased by 9.91% to $4.1. The market value of their outstanding shares is at $78.5 million. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) stock rose 9.9% to $2.33. The market value of their outstanding shares is at $70.4 million. </li>
<li>Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) shares rose 7.03% to $0.3. The company's market cap stands at $8.7 million. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) stock moved upwards by 5.17% to $0.93. The company's market cap stands at $67.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) stock declined by 33.2% to $8.55 during Tuesday's after-market session. The company's market cap stands at $505.1 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) stock decreased by 18.89% to $0.43. The company's market cap stands at $1.8 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock declined by 6.85% to $1.77. The market value of their outstanding shares is at $16.1 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) stock fell 6.57% to $0.87. The company's market cap stands at $27.1 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock fell 6.42% to $3.5. The market value of their outstanding shares is at $54.9 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock fell 5.8% to $0.74. The company's market cap stands at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLDI

CODX

ENTO

GELS

NOTV

PROK

RMTI

RXST

WGRX

WINT

12 Health Care Stocks Moving In Tuesday's After-Market Session

Reported Earlier, SunLink Health Systems Hit With NYSE Deficiency Notice For Failing To Hold Annual Shareholder Meeting For Fiscal Year Ending June 30, 2025

<h3>Gainers</h3>
<ul>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares moved upwards by 216.8% to $0.72 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.9 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares rose 104.73% to $1.73. </li>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) shares rose 78.26% to $0.7. The market value of their outstanding shares is at $159.8 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock moved upwards by 36.43% to $7.17. The market value of their outstanding shares is at $40.0 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares moved upwards by 30.87% to $0.19. The market value of their outstanding shares is at $1.1 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) shares moved upwards by 17.17% to $1.16. The market value of their outstanding shares is at $8.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) stock fell 33.3% to $0.74 during Wednesday's pre-market session. The company's market cap stands at $30.9 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock declined by 17.29% to $2.44. The company's market cap stands at $23.0 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares declined by 13.07% to $0.7. The market value of their outstanding shares is at $2.5 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock decreased by 12.94% to $1.75. The company's market cap stands at $56.8 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) shares fell 12.84% to $7.74. The market value of their outstanding shares is at $28.5 million. </li>
<li>Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) shares declined by 10.64% to $2.1. The company's market cap stands at $106.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CABA

CARM

HSDT

KLTO

KZIA

NCNA

Tempest Therapeutics, Inc. - Common Stock

TPST

VTAK

VXRT

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock increased by 97.3% to $0.45 during Tuesday's after-market session. The company's market cap stands at $4.9 million. </li>
<li>Serina Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SER#AMEX">SER</a>) stock moved upwards by 23.08% to $7.25. The company's market cap stands at $72.2 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock rose 11.08% to $0.26. The company's market cap stands at $1.1 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock increased by 10.12% to $0.87. The company's market cap stands at $3.1 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock moved upwards by 7.97% to $1.75. The market value of their outstanding shares is at $30.6 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) shares moved upwards by 7.07% to $1.06. The market value of their outstanding shares is at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares fell 18.4% to $0.12 during Tuesday's after-market session. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares decreased by 14.92% to $2.51. The market value of their outstanding shares is at $23.6 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares declined by 14.08% to $0.93. The market value of their outstanding shares is at $38.7 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock decreased by 9.88% to $0.25. The market value of their outstanding shares is at $15.1 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock decreased by 6.26% to $1.2. The company's market cap stands at $85.8 million. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) shares declined by 5.52% to $6.25. The company's market cap stands at $168.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTOR

IMNN

INGN

NUWE

<h3>Gainers</h3>
<ul>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) shares increased by 58.0% to $2.07 during Thursday's after-market session. The company's market cap stands at $29.7 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) shares increased by 22.86% to $1.1. The market value of their outstanding shares is at $7.7 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares moved upwards by 13.4% to $5.92. The market value of their outstanding shares is at $158.1 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) shares moved upwards by 7.8% to $0.33. The company's market cap stands at $19.5 million. </li>
<li>SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) stock increased by 7.39% to $1.88. The market value of their outstanding shares is at $17.4 million. </li>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) stock moved upwards by 7.29% to $2.5. The market value of their outstanding shares is at $270.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) shares declined by 14.5% to $0.87 during Thursday's after-market session. The company's market cap stands at $23.7 million. </li>
<li>Nautilus Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAUT#NASDAQ">NAUT</a>) shares fell 8.71% to $0.73. The market value of their outstanding shares is at $91.6 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock declined by 8.16% to $0.37. The market value of their outstanding shares is at $5.8 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares decreased by 7.93% to $0.31. The market value of their outstanding shares is at $8.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock decreased by 7.7% to $0.01. The market value of their outstanding shares is at $3.4 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares declined by 7.56% to $1.1. The company's market cap stands at $18.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

ELEV

FEMY

HCTI

INDP

LIMN

MODV

NAUT

SABS

TNGX

12 Health Care Stocks Moving In Thursday's After-Market Session

SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) reported quarterly losses of $(0.10) per share. This is a 50 percent increase over losses of $(0.20) per share from the same period last year. The company reported $7.32 million in sales this quarter. This is a 1.86 percent decrease over sales of $7.46 million the same period last year.

Earnings

SunLink Health Systems Q3 EPS $(0.10) Up From $(0.20) YoY, Sales $7.32M Down From $7.46M YoY

Atlanta, GA, April 15, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. ("Regional") (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/RHEP#OTCQB">RHEP</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/RHEPA#OTCQB">RHEPA</a>) and SunLink Health Systems, Inc. ("SunLink") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSY#NYSE">SSY</a>) jointly announced today that they have entered into an amended and restated agreement and plan of merger (the "merger agreement"), pursuant to which SunLink will merge with and into Regional (the "merger") in exchange for the issuance of an aggregate of approximately 1,595,401 shares of Regional common stock and 1,408,121 shares of Regional's newly-authorized Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares (the "Regional Series D Preferred Stock") with an initial liquidation preference of $12.50 per share. The merger agreement has been approved by each company's board of directors and completion of the transaction remains subject to the receipt of the approvals of the shareholders of both Regional and SunLink, regulatory approvals and satisfaction of customary closing conditions.

RHEP

RHEPA

Sunlink To Merge With Regional Health Properties In Exchange For Regional Series D Preferred Stock With Initial Liquidation Preference Of $12.50/Shr

<h3>Gainers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock increased by 39.2% to $2.06 during Monday's pre-market session. The market value of their outstanding shares is at $1.5 million. </li>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) shares moved upwards by 20.2% to $1.19. The market value of their outstanding shares is at $5.2 million. </li>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) stock rose 19.18% to $2.05. The market value of their outstanding shares is at $2.8 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares rose 17.94% to $1.7. The market value of their outstanding shares is at $3.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 17.7% to $69.01. The company's market cap stands at $898.0 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock rose 16.54% to $0.36. The market value of their outstanding shares is at $10.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock declined by 44.1% to $1.0 during Monday's pre-market session. The market value of their outstanding shares is at $26.8 million. </li>
<li>Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) shares decreased by 37.0% to $1.15. The market value of their outstanding shares is at $19.3 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares decreased by 32.6% to $0.75. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 13.92% to $4.27. The market value of their outstanding shares is at $49.1 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) shares decreased by 12.46% to $0.95. The market value of their outstanding shares is at $6.6 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock fell 10.89% to $0.38. The company's market cap stands at $1.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLR

CAPS

PRPH

RNAZ

THAR

12 Health Care Stocks Moving In Monday's Pre-Market Session

SunLink Health Systems Q2 EPS $(0.19) Down From $(0.44) YoY; Revenue $7.935M Down From $8.510M YoY

Regional Health Properties shares are trading higher after the company announced an all-stock merger with SunLink Health Systems.

Regional Health Properties, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RHE#AMEX">RHE</a>) and SunLink Health Systems, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) shares traded higher after the companies disclosed a merger agreement.
As part of the deal, Regional Health Properties will issue 1.41 million shares of common stock and 1.41 million shares of newly authorized Series D 8% Cumulative Convertible Redeemable Preferred Stock.
Notably, for every five shares of SunLink common stock, Regional will issue one share of common stock and, subject to adjustments, one share of Series D Preferred Stock.
Post-merger, SunLink shareholders will own about 43% of the combined company.  The Series D Preferred Stock has a $10 liquidation preference and an 8% annual dividend, starting July 1, 2027. Each three shares of Series D Preferred Stock are convertible into one share of Regional common stock.
Upon shareholder approval, SunLink may pay a special dividend, subject to cash availability. No fractional shares will be issued.
Regional anticipates pre-tax cost synergies of $1 million by the end of its fiscal 2026. The transaction, unanimously approved by both companies&#8217; boards, is expected to close in spring 2025, pending customary conditions.
As of December 31, 2024, SunLink reported $17.6 million in total assets with no long-term debt.
Price Action: RHE shares are up 190.3% at $4.499 and, SSY shares rose 19.2% at $1.085 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42812603" target="_blank" rel="noreferrer noopener">Uber CFO Says Stock Undervalued, Initiates $1.5 Billion Accelerated Stock Buyback</a></li>
</ul>
Photo via Shutterstock.

Equities

Small Cap

SunLink Joins Forces With Regional Health Properties In All-Stock Deal: Shares Surge

CORRECTION: Regional And SunLink Announced Merger; SunLink To Merge Into Regional In Exchange For 1.41M Regional Common Shares And Series D Preferred Stock. SunLink Shareholders To Own 43% Of Combined Company

SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) reported quarterly losses of $(0.06) per share. This is unchanged from the same period last year. The company reported $7.92 million in sales this quarter. This is a 7.39 percent decrease over sales of $8.55 million the same period last year.

SunLink Health Systems Q1 EPS $(0.06), Same YoY, Sales $7.92M Down From $8.55M YoY

Legal

Press Releases

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, NARI, SSY on Behalf of Shareholders

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MRNS, RHE, SSY, CTV on Behalf of Shareholders

SunLink Health Systems, Inc. Announces Fiscal 2025 Second Quarter Results

REGIONAL HEALTH PROPERTIES AND SUNLINK HEALTH SYSTEMS REVISE ALL-STOCK MERGER TRANSACTION

SunLink Health Systems, Inc. Announces Fiscal 2025 Third Quarter Results

SunLink Health Systems Announces That It Received a NYSE American LLC Notice Indicating That SunLink Has Fallen Below Certain NYSE American Continued Listing Standards

SunLink Health Systems, Inc Declares Special Cash Dividend Prior to with the Proposed Merger with Regional Health Properties, Inc.

SunLink Health Systems, Inc. Provides Update on Special Cash Dividend Scheduled to Be Paid Prior to SunLink's Proposed Merger with Regional Health Properties, Inc.

SunLink Health Systems, Inc. provides an Update on Proxy Voting for the Proposed Merger with Regional Health Properties, Inc. and Urges Stockholders of Record as of June 20, 2025 to Vote FOR the Proposed Merger by July 28, 2025 at 11:59 PM EDT

SunLink Health Systems, Inc. Adjourns Special Meeting Until August 4, 2025 and Urges Stockholders of Record as of June 20, 2025 to Vote FOR the Proposed Merger With Regional Health Properties, Inc. by August 3, 2025 at 11:59 PM EDT

Comments

SunLink Health Systems

Vendite allo scoperto

SunLink Health Systems (AMEX:SSY) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO